Raymond James Financial Services Advisors, Inc. Aim Immuno Tech Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$69.1 Billion
Q2 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$0.57 - $0.81 $285 - $405	-500 Reduced 1.34%	36,950 $22,000
Q2 2022 Aug 12, 2022	BUY	$0.78 - $1.27 $29,211 - $47,561	37,450 New	37,450 $29,000
Q1 2022 May 11, 2022	SELL	$0.67 - $1.18 $32,461 - $57,171	-48,450 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$1.91 - $2.17 $955 - $1,085	500 Added 1.04%	48,450 $98,000
Q2 2021 Aug 11, 2021	BUY	$1.93 - $2.39 $92,543 - $114,600	47,950 New	47,950 $103,000

Others Institutions Holding AIM

# of Institutions

Shares Held

8.44M

Call Options Held

Put Options Held

Armistice Capital, LLC New York, NY

4.08M
Shares

$1.02 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

1.99M
Shares

$497,176
0.0% of portfolio
Black Rock Inc. New York, NY

698K
Shares

$174,566
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

401K
Shares

$100,256
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

229K
Shares

$57,202
0.0% of portfolio

View Full List

About AIM ImmunoTech Inc.

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $12M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

More about AIM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account